NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

MediciNova Inc (NASDAQ: MNOV)

 
MNOV Technical Analysis
5
As on 9th Jun 2023 MNOV STOCK Price closed @ 2.15 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.41 & Strong Sell for SHORT-TERM with Stoploss of 2.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MNOVSTOCK Price

Open 2.15 Change Price %
High 2.16 1 Day -0.01 -0.46
Low 2.14 1 Week 0.00 0.00
Close 2.15 1 Month 0.03 1.42
Volume 5706 1 Year -0.61 -22.10
52 Week High 3.14 | 52 Week Low 1.95
 
NASDAQ USA Most Active Stocks
TSLA 244.40 4.06%
TTOO 0.07 -12.50%
SOFI 8.18 0.74%
FFIE 0.33 6.45%
PONO 1.72 2.38%
AMD 124.92 3.20%
IDEX 0.06 0.00%
NKLA 0.70 14.75%
AMZN 123.43 -0.66%
AAPL 180.96 0.22%
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
METXW 0.05 150.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
JCIC 22.08 116.68%
AURCW 0.04 100.00%
NOVVW 0.02 100.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
PTIXW 0.01 -66.67%
AGBAW 0.02 -66.67%
MLACW 0.02 -60.00%
MILEW 0.06 -53.85%
RCRTW 0.02 -50.00%
LOTZW 0.01 -50.00%
GSMGW 0.01 -50.00%
DKDCW 0.01 -50.00%
 
 
MNOV
Daily Charts
MNOV
Intraday Charts
Whats New @
Bazaartrend
MNOV
Free Analysis
 
MNOV Important Levels Intraday
RESISTANCE2.19
RESISTANCE2.18
RESISTANCE2.17
RESISTANCE2.16
SUPPORT2.14
SUPPORT2.13
SUPPORT2.12
SUPPORT2.11
 
MNOV Forecast May 2024
4th UP Forecast3.23
3rd UP Forecast2.88
2nd UP Forecast2.67
1st UP Forecast2.46
1st DOWN Forecast1.84
2nd DOWN Forecast1.63
3rd DOWN Forecast1.42
4th DOWN Forecast1.07
 
MNOV Weekly Forecast
4th UP Forecast2.71
3rd UP Forecast2.53
2nd UP Forecast2.42
1st UP Forecast2.31
1st DOWN Forecast1.99
2nd DOWN Forecast1.88
3rd DOWN Forecast1.77
4th DOWN Forecast1.59
 
MNOV Forecast2024
4th UP Forecast4.64
3rd UP Forecast3.84
2nd UP Forecast3.35
1st UP Forecast2.85
1st DOWN Forecast1.45
2nd DOWN Forecast0.95
3rd DOWN Forecast0.46
4th DOWN Forecast-0.34
 
 
MNOV Other Details
Segment EQ
Market Capital 171388704.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
MNOV Address
MNOV
 
MNOV Latest News
 
Your Comments and Response on MediciNova Inc
 
MNOV Business Profile
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California. Address: 4275 Executive Square, La Jolla, CA, United States, 92037
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service